Bird flu latest as major update issued over UK turkeys | UK | News
The increasing threat of bird flu has led to a major breakthrough in the fight against the disease. Veterinarians in the UK have begun vaccinating turkeys in the first trial in England, testing cutting-edge vaccines to protect the poultry industry from devastating outbreaks.
The 24-week study, which started on Thursday, targets a small flock under strict regulatory oversight using UK and EU-approved vaccines against highly pathogenic avian influenza (HPAI). While routine poultry vaccination remains banned in Britain, the Veterinary Medicines Directorate has given the green light to this supervised trial to investigate the real-world effectiveness of vaccines.
Türkiye was chosen as a focal point due to their extreme vulnerability; outbreaks trigger rapid, very high mortality rates and damage farms. The trial will measure how well the vaccines support immunity, how well they integrate with surveillance to protect trade and how they are incorporated into the UK’s wider disease control arsenal alongside strict biosecurity protocols.
This comes against a dire backdrop of unprecedented HPAI increases across the UK and Europe since 2020, harming both farmed and wild birds. Mass culls inflicted heavy financial blows and emotional turmoil on keepers; the annual cost to government and industry has risen to £174 million.
Biosecurity Minister Baroness Hayman said: “We know what a terrible impact this disease has on our farmers and our poultry industry every year.
“The start of new vaccine trials is a significant step forward in our fight against this disease and will contribute to global research efforts. We hope that vaccines can be used as an additional tool to control bird flu in the UK and protect the UK’s biosecurity and food supply.”
UK Chief Veterinary Officer Christine Middlemiss echoed the optimism, describing the trial as “really important” to understanding the roll-out of the HPAI vaccine. He said: “They have the potential to be a really valuable additional tool to help us protect birds from infection.” He called on keepers to maintain “strict biosecurity” as the ultimate defence: “I urge all bird keepers to continue to take the necessary steps to prevent the spread of bird flu on their premises.”
Animal and Plant Health Agency expert Professor Ashley Banyard underlined that there has been a global scourge since 2020 and that variable effects make predictions difficult. He explained: “Evaluating the ability of these vaccines to induce an immune response in turkeys would be a good indicator of the suitability of these vaccines as tools to protect birds against H5N1.”
The initiative stems from a July 2025 report by the UK HPAI vaccine working group, which flagged turkeys for a domestic field trial after weighing costs, benefits and industry challenges. The findings could shape eventual policy recommendations and potentially reshape how Britain faces this persistent threat.
Similar efforts are underway across borders: Italy and the Netherlands are running their own HPAI vaccine trials as the countries grapple with common challenges. In the UK, vigilance continues to include identifying symptoms early and reporting promptly to stop the spread.
Defra officials emphasize that biosecurity fundamentals such as safe housing and hygiene are non-negotiable. But given that wild birds fuel transmission, vaccines could offer a vital extra layer, easing the pressure on an industry already battered by supply chain issues and rising feed costs.
This trial marks a turning point from reactive culling to proactive prevention, potentially saving millions in losses and countless birds.
As Europe reels from new waves – France alone has culled more than 20 million birds in recent seasons – the UK’s data could inform international strategies and encourage cross-border cooperation.
As trials continue over the coming months, experts will closely monitor antibody responses, side effects and commercial outcomes. Early results could pave the way for wider rollout, but only if efficacy is demonstrated without compromising exports; It’s a delicate balance in a global market wary of inoculated meat.
